Deal Watch: Takeda Seeks A Crescendo With Collaboration On New Type Of Cancer Compound
Executive Summary
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
You may also be interested in...
Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.
AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
AstraZeneca has out-licensed a promising respiratory compound to Insmed Inc saying the US-based group is better placed to advance AZD7986 in bronchiectasis, a rare pulmonary disorder.
Intas Builds Europe Scale With £603m Teva Deal
Intas Pharmaceuticals of India has acquired certain Teva assets in Europe – a transaction that is expected to give the unlisted Indian group significantly expanded scale in the region.